Search

Search Results

• 

  Photocarcinogenicity of selected topically applied dermatological drugs: calcineurin inhibitors, corticosteroids, and vitamin D analogs

  Catharina Margrethe Lerche, Hans Christian Wulf

  e13

  14-09-2010

  https://doi.org/10.4081/dr.2010.e13

  2228

  PDF: 889

  HTML: 182

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2859

  PDF: 1015

  HTML: 39
• 

  Atopic dermatitis: a brief review of recent advances in its management

  Sultan Daghafak Alenazi

  23-05-2023

  https://doi.org/10.4081/dr.2023.9678

  2520

  PDF: 1454

  HTML: 128
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1169

  PDF: 576

  HTML: 28

• Psoriasiform eruption induced by dupilumab successfully treated with upadacitinib

  Mattia Minghini, Natale Schettini, Lucrezia Pacetti, Chiara Bocchi, Alessandro Borghi

  16-10-2025

  https://doi.org/10.4081/dr.2025.10588

  432

  PDF: 218

  HTML: 4

• Analysis of interleukin 7 and platelet-derived growth factor-BB mRNA expression as potential markers in erythema nodosum leprosum

  Fitri Kadarsih Banjar, Farida Tabri, Sri Vitayani Muchtar, Mochammad Hatta, Khaeruddin Djawad, Farida Ilyas, Sitti Musafirah, Muhammad Nasrum Massi, Agussalim Bukhari, Andi Alfian Zainuddin

  12-09-2023

  https://doi.org/10.4081/dr.2023.9773

  990

  PDF: 492

  HTML: 28

• Intra-class switch among interleukin-17 inhibitors for the treatment of plaque psoriasis: a single-center experience

  Gioele Ghezzi, Luciano Ibba, Luigi Gargiulo, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  12-11-2024

  https://doi.org/10.4081/dr.2024.10080

  1378

  PDF: 752

  HTML: 48
• 

  Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI)

  Luca Fania, Cesare Massone, Francesco Cusano, Fabrizio Fantini, Elena Dellambra, Tonia Samela, Francesca Passarelli, Roberto Morese, Tommaso Tartaglione, Marino Maggiore, Piercarlo Gentile, Mattia Falchetto Osti, Francesca Sampogna, Sabatino Pallotta, Damiano Abeni, Paolo Marchetti, Luigi Naldi, ADOI steering group*

  05-08-2021

  https://doi.org/10.4081/dr.2021.9278

  3200

  PDF: 844

  HTML: 57
• 

  Effects of canary seed on two patients with disseminated granuloma annulare

  Lily Park, Claudia Green, Sergey Arutyunyan, Gabriella Vasile, Christopher Buckley, Eduardo Weiss

  23-12-2022

  https://doi.org/10.4081/dr.2023.9614

  1652

  PDF: 569

  HTML: 525

• Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab

  Angela Fico, Edoardo Mortato, Claudia Paganini, Marina Talamonti, Cosimo Di Raimondo, Dionisio Silvaggio, Luca Bianchi, Marco Galluzzo

  30-05-2025

  https://doi.org/10.4081/dr.2025.10414

  891

  PDF: 472

  HTML: 54

• Cost analysis in the management of moderate-to-severe psoriasis: comparison between conventional and biological systemic therapies

  Edoardo Mortato, Silvia Baratta, Luca Rubino, Anna Paola De Caro, Francesco Loconsole

  19-06-2023

  https://doi.org/10.4081/dr.2023.9755

  910

  PDF: 443

  HTML: 25

• Refractory pityriasis rubra pilaris treated with abrocitinib

  Filip Rob

  09-01-2025

  https://doi.org/10.4081/dr.2025.10105

  518

  PDF: 327

  HTML: 25

• New and emerging therapies in cutaneous T-cell lymphoma

  Gabriele Roccuzzo, Nicole Macagno, Silvia Giordano, Paolo Fava, Pietro Quaglino

  02-10-2024

  https://doi.org/10.4081/dr.2024.10002

  1227

  PDF: 691

  HTML: 110

• Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus

  Andrea Bassi, Vincenzo Piccolo, Grazia Gallippi, Giuseppe Argenziano, Michela Magnano, Carlo Mazzatenta

  11-09-2025

  https://doi.org/10.4081/dr.2025.10458

  446

  PDF: 359

  HTML: 24

• A bibliometric study of the top 100 most-cited articles on melanoma: insights into research trends and characteristics

  Jinhao Zhang, Xiangze Meng, Yun Wang, Wei Liu

  18-08-2025

  https://doi.org/10.4081/dr.2025.10435

  591

  PDF: 334

  SUPPLEMENTARY MATERIAL: 182

  HTML: 19

• Hidradenitis suppurativa: state-of-the-art review and update

  Marco Virone, Elena Zappia, Alberto Di Caro, Davide Carlesimo, Nicoletta Bernardini, Giovanni Pellacani, Antonio Giovanni Richetta, Steven Paul Nisticò, Annunziata Dattola

  27-08-2025

  https://doi.org/10.4081/dr.2025.10328

  1347

  PDF: 856

  HTML: 18

• Venous thromboembolism in bullous pemphigoid: current evidence from an updated systematic review

  Atheer G. Almutairi, Abeer G. Almutairi, Rahaf R. Almutairi, Asem Shadid, Alhanouf A. Bin Dakhil, Lamia Alakrash

  29-01-2025

  https://doi.org/10.4081/dr.2025.10257

  904

  PDF: 418

  SUPPLEMENTARY MATERIAL: 91

  HTML: 12

• A microRNA focus on acne

  Sarah Gordon, Alison M. Layton, Sandra Fawcett, Kehinde Ross

  02-02-2024

  https://doi.org/10.4081/dr.2024.9902

  1161

  PDF: 751

  HTML: 73

• Upadacitinib as a potential option for the management of paradoxical eczema induced by interleukin-23 inhibitors

  Anna Paola Lugli, Niccolò Gori, Elena Ippoliti, Benedetta Ambrosio, Ketty Peris

  03-02-2026

  https://doi.org/10.4081/dr.2026.10644

  770

  PDF: 514

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  1094

  PDF: 579

  SUPPLEMENTARY MATERIAL: 188

  HTML: 24
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1431

  PDF: 432

  HTML: 54
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1231

  PDF: 865

  HTML: 50
• 

  Mortality risk factors in febrile ulceronecrotic Mucha- Habermann disease: a systematic review of therapeutic outcomes and complications

  Vasiliki Tasouli-Drakou, May Nguyen, Hannah Guinn, Omron Hassan, Sneha Butala, Sheshanna Phan

  21-11-2022

  https://doi.org/10.4081/dr.2022.9492

  1829

  PDF: 703

  HTML: 92

• Efficacy and safety of risankizumab in patients with erythrodermic and sub-erythrodermic psoriasis: a case series

  Andrea D'Arino, Maria Concetta Fargnoli, Pasquale Frascione, Chiara Assorgi, Annunziata Dattola, Viviana Lora, Matteo Megna, Flavia Pigliacelli, Emanuele Vagnozzi, Diego Orsini

  30-07-2025

  https://doi.org/10.4081/dr.2025.10379

  581

  PDF: 395

  HTML: 15
• 

  Telangiectasia Macularis Eruptiva Perstans: more than skin deep

  Casey E. Watkins, Winston B. Bokor, Stuart Leicht, George Youngberg, Guha Krishnaswamy

  e12

  29-07-2011

  https://doi.org/10.4081/dr.2011.e12

  11810

  PDF: 2251

  HTML: 2307